Status:
ENROLLING_BY_INVITATION
Perioperative Treatment Outcomes of Early NSCLC
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
NSCLC
Eligibility:
All Genders
Brief Summary
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes of perioperative NSCLC patients receiving different treatment strategies. According to...
Eligibility Criteria
Inclusion
- Stage I-III NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.
- Patients who have undergone radical lung cancer surgery.
- Patients who have received neoadjuvant treatment before radical lung cancer surgery, including chemotherapy, targeted therapy, or immunotherapy both alone or combined.
Exclusion
- Patients with other previous malignancies, except those who achieved complete remission at least two years before radical lung cancer surgery and did not require additional treatment.
- Patients with incomplete key baseline and treatment information，including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant.
- Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
- Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.
Key Trial Info
Start Date :
November 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06610240
Start Date
November 1 2024
End Date
October 31 2025
Last Update
November 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhong Hua
Shanghai, Shanghai Municipality, China, 200030